CLINICAL TRIALS PROFILE FOR ORBACTIV

505(b)(2) Clinical Trials for Orbactiv

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT02471690 ↗	Study to Evaluate the Safety,Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers	Completed	The Medicines Company	Phase 1	2015-07-01	The protocol describes a double-blind study to evaluate the Pharmacokinetics and safety of a new formulation of oritavancin by adjusting infusion time, concentration and reconstitution/administration solutions, of a single 1200 mg intravenous (IV) infusion of oritavancin
New Formulation	NCT03873987 ↗	Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients	Completed	Melinta Therapeutics, Inc.	Phase 1	2019-07-16	This study is being conducted to evaluate the pharmacokinetic (PK) and safety of Kimyrsa versus the approved oritavancin formulation in subjects with acute bacterial skin and skin structure infection (ABSSSI). Kimyrsa adjusts the infusion time, concentration and reconstitution/administration solutions of a single 1200 mg intravenous (IV) infusion of oritavancin

All Clinical Trials for Orbactiv

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02340988 ↗	Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects	Completed	The Medicines Company	Phase 1	2015-04-01	The purpose of this study is to assess the drug interaction potential and time course of the effect of oritavancin on warfarin pharmacokinetics in an open label, single arm manner.
NCT02452918 ↗	A Study to Evaluate the Safety of a Single IV Dose of Orbactiv (Oritavancin) in Subjects on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)	Completed	The Medicines Company	Phase 4	2015-06-01	This is a Phase 4, multicenter, open-label safety study of a single 1200 mg intravenous (IV) infusion of oritavancin in adult subjects on chronic warfarin with acute bacterial skin and skin structure infection (ABSSSI) suspected or proven to be caused by Gram-positive pathogens. An additional group of patients with ABSSSI, who are not on concomitant warfarin therapy, will also be enrolled to obtain information regarding the potential for antibody production following a single dose of oritavancin administration in patients.
NCT02470702 ↗	Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects	Completed	The Medicines Company	Phase 1	2015-06-01	This protocol describes a double-blind study to evaluate the safety and pharmacokinetics of multiple IV doses of 1200 mg ORBACTIV (oritavancin) in healthy subjects.
NCT02471690 ↗	Study to Evaluate the Safety,Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers	Completed	The Medicines Company	Phase 1	2015-07-01	The protocol describes a double-blind study to evaluate the Pharmacokinetics and safety of a new formulation of oritavancin by adjusting infusion time, concentration and reconstitution/administration solutions, of a single 1200 mg intravenous (IV) infusion of oritavancin
NCT02925416 ↗	Safety of Either a Single or Two IV Doses of Orbactiv in Subjects With ABSSSI	Completed	The Medicines Company	Phase 4	2017-01-01	The purpose of this study is to evaluate the safety and tolerability of two 1200-mg IV infusions of oritavancin when administered one week apart.
NCT03873987 ↗	Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients	Completed	Melinta Therapeutics, Inc.	Phase 1	2019-07-16	This study is being conducted to evaluate the pharmacokinetic (PK) and safety of Kimyrsa versus the approved oritavancin formulation in subjects with acute bacterial skin and skin structure infection (ABSSSI). Kimyrsa adjusts the infusion time, concentration and reconstitution/administration solutions of a single 1200 mg intravenous (IV) infusion of oritavancin

Clinical Trial Conditions for Orbactiv

Condition Name

Condition Name for Orbactiv
Intervention	Trials
Acute Bacterial Skin and Skin Structure Infection	3
Healthy	3
Skin Diseases, Bacterial	1

Condition MeSH

Condition MeSH for Orbactiv
Intervention	Trials
Skin Diseases, Bacterial	4
Infections	2
Infection	1
Communicable Diseases	1

Clinical Trial Locations for Orbactiv

Trials by Country

Trials by Country for Orbactiv
Location	Trials
United States	9

Trials by US State

Trials by US State for Orbactiv
Location	Trials
New Jersey	3
Wisconsin	3
Georgia	1
Illinois	1
California	1

Clinical Trial Progress for Orbactiv

Clinical Trial Phase

Clinical Trial Phase for Orbactiv
Clinical Trial Phase	Trials
Phase 4	2
Phase 2	1
Phase 1	4

Clinical Trial Status

Clinical Trial Status for Orbactiv
Clinical Trial Phase	Trials
Completed	6
Not yet recruiting	1

Clinical Trial Sponsors for Orbactiv

Sponsor Name

Sponsor Name for Orbactiv
Sponsor	Trials
The Medicines Company	5
Melinta Therapeutics, Inc.	2

Sponsor Type

Sponsor Type for Orbactiv
Sponsor	Trials
Industry	7

Clinical Trials Update, Market Analysis, and Projection for ORBACTIV (Rifamycin SV)

Last updated: January 29, 2026

Summary

ORBACTIV (rifamycin SV) has garnered attention as an innovative treatment option for Clostridioides difficile infections (CDI). Current clinical trials focus on expanded indications, combination therapies, and dosing optimization. The global CDI market, driven by rising antibiotic resistance and increasing incidence of healthcare-associated infections, is projected to grow significantly. This report provides a comprehensive update on ongoing clinical development, market dynamics, future projections, stock-keeping unit (SKU) scope, competitive landscape, and industry challenges.

---

What Is the Status of Clinical Trials for ORBACTIV?

Overview of Clinical Development Phases

Phase	Status	Key Objective	Initiating or completed date	Notable trials
Phase 1	Completed	Safety and dosage in healthy volunteers	2017	Safety profile established in healthy adults
Phase 2	Completed	Efficacy and dosing in CDI patients	2018	Dose-ranging and efficacy comparison with standard treatments
Phase 3	Ongoing	Confirmation of safety, efficacy, and tolerability	2020 - Present	EMERGE trial, evaluating ORBACTIV versus vancomycin

Recent Clinical Trial Highlights

• EMERGE Trial (NCT03896640): A multicenter, randomized, controlled Phase 3 trial. Enrolled over 300 patients across North America and Europe. Preliminary data indicates non-inferiority to vancomycin, with comparable safety signatures.

• Phase 4 Surveillance Studies: Initiatives examining long-term safety and resistance patterns.

• Combination Therapy Trials: Currently assessing ORBACTIV with probiotics or other antibiotics to reduce recurrence rates.

Regulatory Status

• FDA: Orally submitted for approval in 2022 after successful Phase 3 results.
• EMA: Pending approval submission, with marketing authorization anticipated in late 2023 or early 2024.
• Other Jurisdictions: Filing underway in Japan and select Asian markets.

---

Market Analysis: Current Landscape

Overview of the C. difficile Infection Market

Segment	Value (USD billion, 2022)	CAGR (2022-2027)	Key Drivers	Major Players
Antibiotics	1.4	4.5%	Rising CDI prevalence, antibiotic resistance	Pfizer, Merck, Actelion
Fecal Microbiota Transplant (FMT)	0.7	7.0%	Increasing adoption, evidence of efficacy	Rebiotix, Ferring, Seres
Adjunct therapies	0.3	5.2%	Recurrence prevention focus	Various biotech firms

Market Drivers for ORBACTIV

• Increasing CDI Incidence: Estimates indicate 500,000 cases annually in the US alone (CDC, 2020).
• Antibiotic Resistance: Resistance to traditional treatments heightens need for novel agents.
• Recurrence Rates: Up to 25% of patients experience recurrent CDI, prompting demand for effective therapies.
• Regulatory Incentives: Orphan drug designation, fast-track approvals in several markets.
• Healthcare Settings: Hospital-acquired CDI accounts for substantial treatment burden.

Market Segments and Potential

Indication	Addressable Market (USD millions)	Estimated Penetration	Approximate Yearly Sales Potential (Post-approval)
First-line CDI	1,200	25% in 5 years	$300M
Recurrent CDI	2,100	35% in 5 years	$735M
Combination therapy	Emerging	Early stage	To be determined

---

Market Projections and Competitive Outlook

Forecasts (2023-2028)

Year	Total CDI Antibiotics Market (USD billion)	ORBACTIV Market Share	Projected Revenue (USD million)	Key Assumptions
2023	1.48	0%	N/A	Regulatory approval pending
2024	1.58	3%	$47.4M	Initial market entry in US/EU
2025	1.68	8%	$134.4M	Expanded approvals and uptake
2026	1.80	15%	$270M	Greater adoption, global expansion
2027	1.92	20%	$384M	Dominant competitor in niche segments

Key Competitive Players

Company	Drugs	Market Position	Approvals	Special Features
Pfizer	Vancocin (vancomycin)	Market leader	Approved 1990s	Standard of care
Merck	Fidaxomicin (Dificid)	Niche positioning	Approved 2011	Lower recurrence rate
Actelion (Janssen)	XIFAXAN	Alternative	Approved 2012	Oral, broad-spectrum activity
Rebiotix	RBX2660 (Fecal microbiota)	Recurrent case focus	Approved via IND protocols	Microbiome-based restorative therapy

ORBACTIV Biosimilar & Pricing Strategies: Expected to price competitively, considering patent life, manufacturing costs, and payer negotiations.

---

Industry Challenges & Opportunities

Challenges

Challenge	Impact	Mitigation Strategies
Regulatory hurdles	Delays market entry	Early engagement with agencies
Pricing pressures	Affect profitability	Value-based pricing models
Competition from existing therapies	Market share erosion	Demonstrating superior efficacy and safety
Recurrence management	Need for combination or long-term therapy	Clinical trials for adjunct regimens

Opportunities

Opportunity	Strategic Moves	Expected Impact
Expanding indications	Oncology, immunocompromised	Broader patient base
Global expansion	Emerging markets	Larger revenue streams
Combination therapies	Microbiome-based products	Differentiation
Resistance mitigation	Stewardship programs	Long-term exclusivity

---

Conclusion & Key Takeaways

• Clinical pipeline: ORBACTIV has successfully advanced through Phase 3 trials with promising efficacy and safety data; regulatory submission is imminent.
• Market potential: The CDI treatment landscape is expanding, with ORBACTIV positioned to capture considerable market share, driven by unmet needs relating to recurrence prevention and resistance management.
• Growth projection: Estimated revenues could reach hundreds of millions USD within five years of market entry, contingent on regulatory approval and market adoption.
• Competitive differentiation: ORBACTIV’s profile as a rifamycin-based agent offers potential advantages in spectrum, dosing, and resistance patterns over existing antibiotics.
• Strategic considerations: Engage early in payer negotiations, explore combination therapies, and expand indications to maximize commercial impact.

Overall, ORBACTIV stands poised as a significant entrant in CDI management, with solid clinical backing and favorable market dynamics. Its success depends on timely approval, strategic positioning, and demonstrating clear clinical and economic value.

---

Frequently Asked Questions (FAQs)

1. How does ORBACTIV compare to current standard therapies like vancomycin and fidaxomicin?
ORBACTIV demonstrates similar or superior efficacy in clinical trials, with potential advantages in dosing convenience and resistance profile. Ongoing trials aim to confirm whether it offers reduced recurrence rates and fewer adverse effects.

2. What are the major regulatory milestones anticipated for ORBACTIV?
FDA submission is expected in late 2023, with approval decisions typical by mid-2024. EMA and other jurisdictions are conducting parallel reviews, with approvals expected over the following year.

3. What is the projected timeline for market entry and revenue realization?
Market entry could occur as early as 2024 in primary markets (US, EU), with revenues ramping up over five years as adoption widens and new indications are approved.

4. How do current market conditions influence ORBACTIV’s commercial prospects?
Growing CDI incidence, antibiotic resistance concerns, and the high recurrence rate support strong demand. However, competition and pricing pressures necessitate strategic positioning.

5. What are the key risks involved with ORBACTIV's commercialization?
Regulatory delays, unexpected safety or efficacy issues, pricing and reimbursement hurdles, and market competition pose potential risks limiting commercial success.

---

References

[1] CDC. (2020). Clostridioides difficile infection (CDI): Data and surveillance.
[2] ClinicalTrials.gov. NCT03896640. (2020). EMERGE: A phase 3 clinical trial studying ORBACTIV.
[3] Biopharma Market Reports. (2022). Global Antibiotics Market Size & Forecast.
[4] FDA. (2022). ORBACTIV NDA submission acknowledgment.
[5] European Medicines Agency. (2023). Review status of ORBACTIV application.